• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

    5/31/22 7:30:00 AM ET
    $BTX
    Get the next $BTX alert in real time by email

    SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief Financial Officer.

    "Matt's deep experience in cell therapy product development was an important consideration in Brooklyn's choice to license Factor's RNA development platform, which is the foundation of our current development programs. Therefore, it is only fitting that he take on the mantle to lead Brooklyn," said Charles Cherington, Brooklyn's Chairman of the Board. "On behalf of the Board of Directors, I would like to thank Howard for his service and many contributions to the Company. I am also delighted that Andrew Jackson has joined our team as Chief Financial Officer at such an exciting time for the company. His impressive track record in financing both commercial and clinical-stage biotech companies will be critical as the company enters its next phase of growth."

    "I am excited for this opportunity to lead Brooklyn ImmunoTherapeutics and to help realize the full potential of the company," said Dr. Matt Angel, Brooklyn's Interim Chief Executive Officer and President. "I look forward to leveraging my experience as CEO of an mRNA-focused biotechnology company to help advance Brooklyn's therapeutic platform."

    Dr. Angel is an experienced biotechnology entrepreneur and executive, having led Factor Bioscience Inc. as CEO since its founding in 2011. Dr. Angel is Co-Founder of the immuno-oncology company, Exacis Biotherapeutics, where he serves as Scientific Advisory Board Chair, and the cell therapy company, Novellus Therapeutics, which was acquired by Brooklyn in 2021. Dr. Angel has deep experience in cell therapy product development, intellectual property protection and licensing, contract negotiation, including collaboration and licensing agreements, and has raised more than $150 million through grants, equity financings, and M&A. A pioneer in mRNA technology, Dr. Angel is a prolific inventor with more than 100 patents covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies. Dr. Angel received his Ph.D. from the Massachusetts Institute of Technology, where he studied immunology and synthetic RNA.

    Mr. Jackson joins the Company from Ra Medical Systems, a medical device company focused on vascular diseases where he served as its Chief Financial Officer and Secretary and for a period, its Interim Chief Executive Officer. Mr. Jackson has held several senior financial positions, including Chief Financial Officer, at AltheaDx, Inc, a commercial stage molecular diagnostics company specializing in precision medicine and Celladon Corporation, a publicly-traded, clinical stage gene therapy company, as well as senior financial positions at Sapphire Energy, an industrial biotechnology company. Mr. Jackson received a MSBA in Finance in December 2006 from San Diego State University and a BSB in Accounting in June 1992 from the University of Minnesota. Mr. Jackson is also a certified public accountant (inactive).

    Postponement of 2022 Annual Meeting

    In connection with Dr. Angel's and Mr. Jackson's appointments, together with the other events disclosed by the Company in its Current Report on Form 8-K filed today with the Securities and Exchange Commission, the Board determined to postpone the Company's 2022 Annual Meeting, currently scheduled for June 7, 2022, to a date to be determined. The Board will both determine the date for the Annual Meeting and establish a new record date for the Annual Meeting, and, based on this record date, the Company will deliver a new notice of the Annual Meeting to stockholders entitled to receive notice of the Annual Meeting. Additionally, the Company expects to file a new proxy statement on Schedule 14A in respect of the Annual Meeting.

    About Brooklyn ImmunoTherapeutics

    Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.

    Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that are not statements of historical fact and may be identified by terminology such as "believe," "could," "estimate," "expect," "plan," "possible," "potential," "project," "will" or other similar words and the negatives of such words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those stated or implied in any forward-looking statement as a result of various factors, including, but not limited to, uncertainties related to: (i) the evolution of Brooklyn's business model into a platform company focused on cellular, gene editing and cytokine programs; (ii) Brooklyn's ability to successfully, cost-effectively and efficiently develop its technology and products; (iii) Brooklyn's ability to successfully commence clinical trials of any products on a timely basis or at all; (iv) Brooklyn's ability to successfully fund and manage the growth of its development activities; (v) Brooklyn's ability to obtain regulatory approvals of its products for commercialization; and (vi) uncertainties related to the impact of the COVID-19 pandemic on the business and financial condition of Brooklyn, including on the timing and cost of its clinical trials. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this communication speak only as of the date on which they were made, and Brooklyn does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law. Factors that may cause Brooklyn's actual results from those expressed or implied in forward-looking statements contained in this press release are more fully disclosed in Brooklyn's periodic public filings with the U.S. Securities and Exchange Commission, particularly under the heading "Risk Factors" in Brooklyn's Annual Report on Form 10-K for the year ended December 31, 2021.

    Investor Relations Contact:

    Solebury Trout

    917-936-8430

    [email protected]

    Media Contact:

    Michael V. Morabito, Ph.D.

    Solebury Trout

    917-936-8430

    [email protected]



    Primary Logo

    Get the next $BTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BTX

    DatePrice TargetRatingAnalyst
    12/29/2021$9.00Overweight
    Cantor Fitzgerald
    10/6/2021$20.00Buy
    Maxim Group
    More analyst ratings

    $BTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Brooklyn with a new price target

      Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00

      12/29/21 7:03:49 AM ET
      $BTX
    • Maxim Group initiated coverage on Brooklyn ImmunoTherapeutics with a new price target

      Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00

      10/6/21 7:53:44 AM ET
      $BTX

    $BTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

      SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief

      5/31/22 7:30:00 AM ET
      $BTX
    • Amarin Announces Appointment of New Directors and Board Leadership Changes

      Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta

      5/19/22 8:23:13 AM ET
      $AMRN
      $BTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

      NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati

      1/20/22 7:30:00 AM ET
      $BTX

    $BTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BlackRock Technology and Private Equity Term Trust (BTX) Announces Final Results of Tender Offer

      BlackRock Technology and Private Equity Term Trust (the "Fund") announced today the final results of the Fund's tender offer (the "Tender Offer") for up to 50% of its outstanding common shares (the "Shares"), which expired on July 8, 2025. The Tender Offer was undersubscribed. Therefore, in accordance with the terms and conditions of the Tender Offer, the Fund will purchase all Shares properly tendered from all tendering shareholders. Payment for Shares tendered and accepted are expected to be made approximately five business days after the pricing date (anticipated to be July 16, 2025). The final results of the Tender Offer are provided in the table below: Fund Name Ticker

      7/9/25 8:41:00 PM ET
      $BTX
    • BlackRock Technology and Private Equity Term Trust (BTX) Announces Expiration and Preliminary Results of Tender Offer

      BlackRock Technology and Private Equity Term Trust (the "Fund") announced today the expiration and preliminary results of the Fund's tender offer (the "Tender Offer") for up to 50% of its outstanding common shares (the "Shares"). The Tender Offer commenced on June 9, 2025 and expired at 11:59 p.m. Eastern time on July 8, 2025. Based on preliminary information, the number of Shares properly tendered and not withdrawn is noted in the table below. Fund Name Ticker CUSIP Shares Offered for Repurchase Shares Tendered (Preliminary Results) BlackRock Technology and Private Equity Term Trust BTX 09260Q108 106,669,074 96,627,850

      7/9/25 8:58:00 AM ET
      $BTX
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 7/1/2025 Ex-Date- 7/15/2025 Record- 7/15/2025 Payable- 8/1/2025     National Funds     Ticker     Distribution Change From Prior Distribution   BlackRock Municipal Income Quality Trust*   BYM   $0.055500   - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Qu

      7/1/25 6:02:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable

    $BTX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by BlackRock Technology and Private Equity Term Trust

      SCHEDULE 13D/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)

      7/11/25 5:12:41 PM ET
      $BTX
    • Amendment: SEC Form SC TO-I/A filed by BlackRock Technology and Private Equity Term Trust

      SC TO-I/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)

      7/9/25 8:45:39 PM ET
      $BTX
    • Amendment: SEC Form SC TO-I/A filed by BlackRock Technology and Private Equity Term Trust

      SC TO-I/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)

      7/9/25 3:02:17 PM ET
      $BTX

    $BTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Saba Capital Management, L.P. disposed of $454,458,709 worth of shares (60,675,395 units at $7.49) (SEC Form 4)

      4 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)

      7/10/25 3:48:00 PM ET
      $BTX
    • New insider Minar Stephen Thomas claimed ownership of 1,967 shares (SEC Form 3)

      3 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)

      5/16/25 4:24:38 PM ET
      $BTX
    • SEC Form 3 filed by new insider Cicala Peter

      3 - Eterna Therapeutics Inc. (0000748592) (Issuer)

      2/16/24 5:30:35 PM ET
      $BTX

    $BTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      1/31/24 7:05:56 AM ET
      $BTX
    • SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      1/19/24 10:31:54 AM ET
      $BTX
    • SEC Form SC 13D/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      12/22/23 12:05:20 PM ET
      $BTX

    $BTX
    Financials

    Live finance-specific insights

    See more
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 7/1/2025 Ex-Date- 7/15/2025 Record- 7/15/2025 Payable- 8/1/2025     National Funds     Ticker     Distribution Change From Prior Distribution   BlackRock Municipal Income Quality Trust*   BYM   $0.055500   - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Qu

      7/1/25 6:02:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

      Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

      6/30/25 4:31:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 6/2/2025   Ex-Date- 6/13/2025   Record- 6/13/2025   Payable- 7/1/2025   National Funds    Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust*  BYM  $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN

      6/2/25 5:27:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable